A phase I/II study of Erlotinib/Carboplatin/Pemetrexed/Bevacizumab in chemotherapy-naive patients with EGFR mutation positive advanced non-squamous non-small-cell lung cancer

Trial Profile

A phase I/II study of Erlotinib/Carboplatin/Pemetrexed/Bevacizumab in chemotherapy-naive patients with EGFR mutation positive advanced non-squamous non-small-cell lung cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 May 2016

At a glance

  • Drugs Erlotinib (Primary) ; Bevacizumab; Carboplatin; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top